Please select the eligibility criteria that correspond to the clinical trial below.
Title: A 1-month, Randomized, Double-blind, Placebo-controlled Study of Fenofibrate 145 mg Tablet in Patients With Sleep Apnea Syndrome
Brief Summary: Objectives: to investigate for the potential effect of fenofibrate on symptoms and biological changes associated with sleep apnea syndrome.


Options:
A: Inclusion Criteria:

* Obstructive sleep apnea syndrome, successfully on CPAP therapy
* Residence at low altitude (\<800m)
* Obstructive apnea/hypopnea index \>20/h and a complaint of excessive daytime sleepiness before introduction of CPAP therapy.
* \>15 oxygen desaturations/h (\>3% dips) during an ambulatory nocturnal pulse oximetry performed at the end of a 4-night period without CPAP

Exclusion Criteria:

* Sleep disorders other than OSA.
* More than mild cardiovascular disease, unstable or recently diagnosed (within the last 6 months) cardiovascular disease such as arterial hypertension, coronary artery or cerebrovascular disease.
* Any lung disease, pulmonary hypertension.
* Chronic rhinitis.
* Treatment with drugs that affect respiratory center drive (benzodiazepines or other sedatives or sleep inducing drugs, morphine or codeine derivates), stimulants (modafinil, methylphenidate, theophylline)
* Internal, neurologic or psychiatric disease that interfere with sleep quality.
* Previous intolerance to moderate or low altitude (\<2600m).
* Exposure to altitudes \>1500m for \>1 day within the last 4 weeks before the study
B: Inclusion Criteria:

* Diagnosis of Alzheimer's disease based on the probability criteria of the Alzheimer's Disease and Related Disorders Association
* Rated 1 and 2 (mild to moderate level) on the Brazilian version of the Clinical Dementia Rating

Exclusion Criteria:

* Other causes of dementia
* Other severe medical or psychiatric disease
* Clinical indication of psychoactive drugs other than experimental drug
C: Inclusion Criteria:

* Having previous diagnosis of sleep apnea not treated with Continuous Positive Airway Pressure (CPAP) or presenting clinical symptoms of sleep apnea
* Overweight or obese, with BMI \>= 25 kg/m² and \< 40 kg/m².
* Known moderate hypertriglyceridemia, with fasting Triglycerides level \>= 2.0 and \< 6.0 mmol/L within 3 months before the inclusion.

Exclusion Criteria:

* indication for immediate CPAP
* other known endocrine disease, except treated and adequately controlled hypothyroidism
* renal failure or plasma creatinine level \>130 µmol/L
* current chronic liver disease or ALanine Amino Transferase (ALT)\> 2 times the upper normal limit (UNL)
* symptomatic gallbladder disease
* known muscular disease or creatine phosphokinase (CK) \> 3 times UNL.
D: Inclusion Criteria:

* Children \>6 years of age and \< 12 years of age, who snore and have an apnea hypopnea index (AHI) \< or equal 7 or Respiratory arousal index \> or equal 2

Exclusion Criteria:

* Hypersensitivity to budesonide
* Recent nasal trauma
* Nasal surgery or nasal septum perforation
* Current therapy with drugs interacting with budesonide (erythromycin clarythromycin, ketoconazole and cimetidine)
* Immunodeficiency or immunosuppressant therapy
* Craniofacial, neuromuscular, syndromic or defined genetic abnormalities
* Acute upper respiratory tract infection
* Systemic corticosteroid therapy or antibiotic therapy in the 2 weeks previous to the study, and
* Children who already had adenotonsillectomy in the past 12 months.

Answer: C